Prices delayed by at least 15 minutes | Print
Immupharma PLC (IMM)
ORD 1PCompany profile
ImmuPharma PLC is a drug discovery and development company. The pipeline of the company includes novel peptide-based therapeutics within two therapy areas: autoimmunity & inflammation, and anti-infectives. The company's drug candidate is Lupuzor, which treats lupus and a life-threatening autoimmune disease.
Address
One Bartholomew Close
London
GBR
EC1A 7BL
Telephone
+44 2071524080
Forecast key dates
| Name | Key Date |
|---|---|
| ImmuPharma PLC Second Quarter Earnings Results for 2024 | 2024-08-30T00:00:00 |
| ImmuPharma PLC Annual General Meeting for 2023 | 2024-06-28T11:00:00 |
| ImmuPharma PLC Annual Report for 2023 | 2024-06-06T00:00:00 |
| ImmuPharma PLC Fourth Quarter Earnings Results for 2023 | 2024-05-10T00:00:00 |
Previous key dates
| Name | Key Date |
|---|---|
| ImmuPharma PLC Second Quarter Earnings Results for 2023 | 2023-08-31T00:00:00 |
| ImmuPharma PLC Annual General Meeting for 2022 | 2023-06-30T11:00:00 |
| ImmuPharma PLC Annual Report for 2022 | 2023-06-06T00:00:00 |
| ImmuPharma PLC Fourth Quarter Earnings Results for 2022 | 2023-05-11T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.